Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Humacyte, Inc. (HUMA)

Coherus Oncology, Inc. and Humacyte, Inc. are both Biotechnology companies. Coherus Oncology, Inc. and Humacyte, Inc. are of similar size ($115.7M and $109.9M). Humacyte, Inc. grew revenue faster over the last twelve months: 149.8% against 61.0%. Coherus Oncology, Inc. has the higher net margin (−259.4% vs −4,448.9%) and the higher return on invested capital (0.00% vs −433.7%). Across the 18 metrics below, Coherus Oncology, Inc. leads on 13 and Humacyte, Inc. on 5.

Valuation

Metric CHRS HUMA Biotechnology median
P/E n/m n/m 10.60
P/S 2.34 48.58 9.40
P/B 1.96 3.30 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 4.44 41.40 9.02
Earnings yield (133.77%) (111.36%) (32.88%)
Free cash flow yield (156.84%) (94.68%) (23.13%)

Profitability

Metric CHRS HUMA Biotechnology median
Gross margin 68.94% (494.58%) 68.51%
Operating margin (311.56%) (5,240.78%) 0.00%
Net margin (259.41%) (4,448.89%) 0.00%
Free cash flow margin (365.22%) (4,599.72%) 0.00%
Return on equity (146.27%) (534.42%) (51.96%)
Return on assets (41.90%) (68.16%) (46.06%)
Return on invested capital 0.00% (433.66%) 0.00%

Growth

Metric CHRS HUMA Biotechnology median
Revenue growth (TTM) 61.00% 149.82% 6.76%
EPS growth (last fiscal year) 472.00% 79.37% 29.88%
Revenue growth, 5-year CAGR (38.41%) — 9.75%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS HUMA Biotechnology median
Debt to equity 0.61 2.07 0.00
Current ratio 1.77 6.21 4.97
Net debt to EBITDA 0.76 (0.12) 1.01

Dividend

Metric CHRS HUMA Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CHRS HUMA Biotechnology median
Market cap 115.71m 109.87m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack